Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Sarizotan

Generic Name: Sarizotan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₁FN_₂O

CAS Number: 351862-32-3

Unique Ingredient Identifier: 467LU0UCUW

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in schizophrenia and schizoaffective disorders and parkinson's disease.

Associated Conditions

No associated conditions information available.

Clinical Trials

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Phase 2

Terminated

Posted: 2016/06/03

Sponsor:Newron Pharmaceutica...

ID:NCT02790034

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Phase 2

Completed

Posted: 2006/04/13

Sponsor:EMD Serono

ID:NCT00314288

Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Not Applicable

Terminated

Posted: 2006/04/04

Sponsor:Centre for Addiction...

ID:NCT00310661

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Phase 3

Completed

Posted: 2005/03/16

Sponsor:EMD Serono

ID:NCT00105508

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Phase 3

Completed

Posted: 2005/03/16

Sponsor:EMD Serono

ID:NCT00105521

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy

Drug Development Updates

Sarizotan

Overview

Background

Indication

Associated Conditions

Clinical Trials

FDA Approved Products

Singapore Approved Products

Related News

Acadia Pharmaceuticals Seeks European Approval for Trofinetide in Rett Syndrome

Drug Development Updates